EXOSC3 [The Human Chemical-Genetic Interaction Map Project]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
======= EXOSC3 =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: EXOSC3
  * **<color #00a2e8>Official Name</color>**: exosome component 3
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=51010|51010]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/Q9NQT5|Q9NQT5]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=EXOSC3&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20EXOSC3|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/606489|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**:  This gene encodes a non-catalytic component of the human exosome, a complex with 3'-5' exoribonuclease activity that plays a role in numerous RNA processing and degradation activities. Related pseudogenes of this gene are found on chromosome 19 and 21. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Jun 2012]. 
  * **<color #00a2e8>UniProt Summary</color>**:  Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defects, thereby limiting or excluding their export to the cytoplasm. The RNA exosome may be involved in Ig class switch recombination (CSR) and/or Ig variable region somatic hypermutation (SHM) by targeting AICDA deamination activity to transcribed dsDNA substrates. In the cytoplasm, the RNA exosome complex is involved in general mRNA turnover and specifically degrades inherently unstable mRNAs containing AU-rich elements (AREs) within their 3' untranslated regions, and in RNA surveillance pathways, preventing translation of aberrant mRNAs. It seems to be involved in degradation of histone mRNA. The catalytic inactive RNA exosome core complex of 9 subunits (Exo-9) is proposed to play a pivotal role in the binding and presentation of RNA for ribonucleolysis, and to serve as a scaffold for the association with catalytic subunits and accessory proteins or complexes. EXOSC3 as peripheral part of the Exo-9 complex stabilizes the hexameric ring of RNase PH-domain subunits through contacts with EXOSC9 and EXOSC5. {ECO:0000269|PubMed:11782436, ECO:0000269|PubMed:17545563, ECO:0000269|PubMed:19056938, ECO:0000269|PubMed:21255825}.

<button type='default' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
No Pfam Domain information is available for this gene.
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|nuclear retention of pre-mRNA with aberrant 3-ends at the site of transcription|
|nuclear mRNA surveillance of mRNA 3-end processing|
|CUT catabolic process|
|CUT metabolic process|
|nuclear polyadenylation-dependent ncRNA catabolic process|
|nuclear polyadenylation-dependent tRNA catabolic process|
|nuclear polyadenylation-dependent rRNA catabolic process|
|nuclear ncRNA surveillance|
|nuclear retention of pre-mRNA at the site of transcription|
|polyadenylation-dependent snoRNA 3-end processing|
|polyadenylation-dependent ncRNA catabolic process|
|exonucleolytic trimming involved in rRNA processing|
|U4 snRNA 3-end processing|
|tRNA catabolic process|
|exonucleolytic trimming to generate mature 3-end of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)|
|polyadenylation-dependent RNA catabolic process|
|rRNA 3-end processing|
|nuclear-transcribed mRNA catabolic process, exonucleolytic, 3-5|
|intracellular mRNA localization|
|snoRNA 3-end processing|
|cytoplasmic exosome (RNase complex)|
|DNA deamination|
|nuclear mRNA surveillance|
|snoRNA processing|
|exoribonuclease activity|
|nuclear RNA surveillance|
|RNA surveillance|
|snoRNA metabolic process|
|nuclear exosome (RNase complex)|
|exosome (RNase complex)|
|rRNA catabolic process|
|somatic recombination of immunoglobulin genes involved in immune response|
|isotype switching|
|somatic diversification of immunoglobulins involved in immune response|
|cleavage involved in rRNA processing|
|maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)|
|somatic recombination of immunoglobulin gene segments|
|transcriptionally active chromatin|
|positive regulation of isotype switching|
|immunoglobulin production involved in immunoglobulin mediated immune response|
|maturation of 5.8S rRNA|
|ncRNA catabolic process|
|snRNA 3-end processing|
|3-5-exoribonuclease activity|
|exonucleolytic catabolism of deadenylated mRNA|
|regulation of isotype switching|
|nuclear-transcribed mRNA catabolic process, exonucleolytic|
|snRNA processing|
|somatic diversification of immunoglobulins|
|somatic diversification of immune receptors via germline recombination within a single locus|
|somatic cell DNA recombination|
|positive regulation of B cell mediated immunity|
|positive regulation of immunoglobulin mediated immune response|
|positive regulation of DNA recombination|
|snRNA metabolic process|
|RNA phosphodiester bond hydrolysis, exonucleolytic|
|positive regulation of immunoglobulin production|
|B cell activation involved in immune response|
|ncRNA 3-end processing|
|somatic diversification of immune receptors|
|regulation of B cell mediated immunity|
|regulation of immunoglobulin mediated immune response|
|nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay|
|regulation of immunoglobulin production|
|DNA modification|
|positive regulation of production of molecular mediator of immune response|
|positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains|
|regulation of DNA recombination|
|positive regulation of adaptive immune response|
|positive regulation of lymphocyte mediated immunity|
|lymphocyte activation involved in immune response|
|positive regulation of leukocyte mediated immunity|
|RNA 3-end processing|
|regulation of production of molecular mediator of immune response|
|regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains|
|regulation of lymphocyte mediated immunity|
|B cell activation|
|immunoglobulin production|
|RNA phosphodiester bond hydrolysis|
|regulation of adaptive immune response|
|positive regulation of B cell activation|
|regulation of mRNA stability|
|production of molecular mediator of immune response|
|regulation of RNA stability|
|tRNA metabolic process|
|positive regulation of DNA metabolic process|
|nuclear-transcribed mRNA catabolic process|
|regulation of mRNA catabolic process|
|regulation of leukocyte mediated immunity|
|immunoglobulin mediated immune response|
|regulation of B cell activation|
|B cell mediated immunity|
|rRNA processing|
|RNA localization|
|mRNA catabolic process|
|positive regulation of immune effector process|
|DNA recombination|
|rRNA metabolic process|
|RNA catabolic process|
|lymphocyte mediated immunity|
|adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains|
|nucleic acid phosphodiester bond hydrolysis|
|ribosome biogenesis|
|regulation of mRNA metabolic process|
|regulation of DNA metabolic process|
|positive regulation of lymphocyte activation|
|nucleobase-containing compound catabolic process|
|lymphocyte activation|
|ncRNA processing|
|positive regulation of leukocyte activation|
|positive regulation of cell activation|
|heterocycle catabolic process|
|cellular nitrogen compound catabolic process|
|aromatic compound catabolic process|
|ribonucleoprotein complex biogenesis|
|regulation of immune effector process|
|ncRNA metabolic process|
|organic cyclic compound catabolic process|
|regulation of lymphocyte activation|
|posttranscriptional regulation of gene expression|
|modification-dependent macromolecule catabolic process|
|regulation of leukocyte activation|
|adaptive immune response|
|leukocyte activation involved in immune response|
|cell activation involved in immune response|
|regulation of cell activation|
|immune system development|
|mRNA metabolic process|
|DNA metabolic process|
|leukocyte mediated immunity|
|regulation of cellular catabolic process|
|nucleolus|
|positive regulation of immune response|
|RNA processing|
|cellular macromolecule catabolic process|
|leukocyte activation|
|regulation of catabolic process|
|macromolecule catabolic process|
|cell activation|
|immune effector process|
|regulation of immune response|
|positive regulation of immune system process|
|positive regulation of developmental process|
|RNA binding|
|cellular macromolecule localization|
|regulation of immune system process|
|RNA metabolic process|
|negative regulation of gene expression|
|positive regulation of multicellular organismal process|
|organic substance catabolic process|
|cellular catabolic process|
|immune response|
|positive regulation of nucleobase-containing compound metabolic process|
|gene expression|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='primary' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp456|Benzoate 20000μM R08 exp456]]|-2.4|
|[[:results:exp79|Q15 2.7μM R02 exp79]]|-1.98|
|[[:results:exp94|Nocodazole 0.1μM R03 exp94]]|-1.94|
|[[:results:exp245|UM0011500 5μM R05 exp245]]|1.8|
|[[:results:exp272|CHIR-124 0.04μM R06 exp272]]|1.81|
|[[:results:exp261|ABT-702 5μM R06 exp261]]|1.85|
|[[:results:exp277|Curcumin 6.5μM R06 exp277]]|1.87|
|[[:results:exp461|BS-181 20μM R08 exp461]]|1.89|
|[[:results:exp101|Nicotinamide 1000μM R03 exp101]]|1.92|
|[[:results:exp16|DABN 2μM R00 exp16]]|1.94|
|[[:results:exp233|EPZ-5676 30μM R05 exp233]]|1.97|
|[[:results:exp61|YM155 0.0002μM R01 exp61]]|2.01|
|[[:results:exp484|GSK-J5 1.5μM R08 exp484]]|2.03|
|[[:results:exp177|Apcin 25μM plus proTAME 2μM R04 exp177]]|2.04|
|[[:results:exp102|Nifuroxazide 5μM R03 exp102]]|2.14|
|[[:results:exp237|NN-Diethyl-meta-toluamide 100μM R05 exp237]]|2.16|
|[[:results:exp219|A-395N 10μM R05 exp219]]|2.17|
|[[:results:exp473|Cincreasin 100μM R08 exp473]]|2.17|
|[[:results:exp390|Pifithrin-alpha 20μM R07 exp390]]|2.24|
|[[:results:exp476|Dihydrosphingosine 8μM R08 exp476]]|2.29|
|[[:results:exp69|Deguelin 0.05μM R02 exp69]]|2.31|
|[[:results:exp247|UM0130462 0.025 to 0.035μM day4 R05 exp247]]|2.58|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
^Gene^Correlation^
|[[:human genes:v:vps28|VPS28]]|0.521|
|[[:human genes:r:rrn3|RRN3]]|0.492|
|[[:human genes:t:tbc1d3g|TBC1D3G]]|0.489|
|[[:human genes:s:sh3bp1|SH3BP1]]|0.486|
|[[:human genes:t:tbc1d3h|TBC1D3H]]|0.486|
|[[:human genes:c:copg1|COPG1]]|0.482|
|[[:human genes:d:dtl|DTL]]|0.476|
|[[:human genes:t:tbc1d3f|TBC1D3F]]|0.474|
|[[:human genes:t:tbc1d3|TBC1D3]]|0.472|
|[[:human genes:p:pan3|PAN3]]|0.469|
|[[:human genes:a:atp6v1c1|ATP6V1C1]]|0.469|
|[[:human genes:p:polr2a|POLR2A]]|0.468|
|[[:human genes:r:rpl14|RPL14]]|0.466|
|[[:human genes:c:copb1|COPB1]]|0.461|
|[[:human genes:t:tceb3c|TCEB3C]]|0.459|
|[[:human genes:n:nsf|NSF]]|0.458|
|[[:human genes:f:fam160a1|FAM160A1]]|0.456|
|[[:human genes:t:tbc1d3i|TBC1D3I]]|0.454|
|[[:human genes:t:tbc1d3e|TBC1D3E]]|0.453|
|[[:human genes:t:tbc1d3l|TBC1D3L]]|0.453|
|[[:human genes:t:tbc1d3k|TBC1D3K]]|0.453|
|[[:human genes:t:tceb3cl|TCEB3CL]]|0.453|
|[[:human genes:t:tbc1d3c|TBC1D3C]]|0.451|
|[[:human genes:r:rpl34|RPL34]]|0.45|
|[[:human genes:p:psmb4|PSMB4]]|0.449|
|[[:human genes:p:psmb2|PSMB2]]|0.448|
|[[:human genes:t:tceb3cl2|TCEB3CL2]]|0.446|
|[[:human genes:i:ik|IK]]|0.446|
|[[:human genes:d:dock6|DOCK6]]|0.446|
|[[:human genes:p:psmc1|PSMC1]]|0.446|
|[[:human genes:p:psmd3|PSMD3]]|0.446|
|[[:human genes:r:rpl35|RPL35]]|0.445|
|[[:human genes:c:cactin|CACTIN]]|0.444|
|[[:human genes:p:prpf19|PRPF19]]|0.442|
|[[:human genes:c:cdc73|CDC73]]|0.439|
|[[:human genes:a:atp6v1b2|ATP6V1B2]]|0.438|
|[[:human genes:n:narfl|NARFL]]|0.437|
|[[:human genes:z:znf655|ZNF655]]|0.435|
|[[:human genes:s:slc4a1|SLC4A1]]|0.433|
|[[:human genes:c:cep192|CEP192]]|0.432|
|[[:human genes:p:psma6|PSMA6]]|0.431|
|[[:human genes:n:nupl1|NUPL1]]|0.43|
|[[:human genes:t:tyms|TYMS]]|0.43|
|[[:human genes:s:snrpa1|SNRPA1]]|0.428|
|[[:human genes:x:xylt2|XYLT2]]|0.427|
|[[:human genes:c:chd4|CHD4]]|0.427|
|[[:human genes:a:atp6v1a|ATP6V1A]]|0.426|
|[[:human genes:k:kctd17|KCTD17]]|0.424|
|[[:human genes:c:ccdc64b|CCDC64B]]|0.423|
|[[:human genes:s:supt5h|SUPT5H]]|0.422|
|[[:human genes:t:tfip11|TFIP11]]|0.422|
|[[:human genes:d:ddtl|DDTL]]|0.422|
|[[:human genes:r:rps12|RPS12]]|0.419|
|[[:human genes:r:rplp1|RPLP1]]|0.418|
|[[:human genes:e:ebna1bp2|EBNA1BP2]]|0.417|
|[[:human genes:d:dnm2|DNM2]]|0.416|
|[[:human genes:e:exosc9|EXOSC9]]|0.416|
|[[:human genes:c:cdt1|CDT1]]|0.416|
|[[:human genes:c:ccdc94|CCDC94]]|0.415|
|[[:human genes:m:mcf2l|MCF2L]]|0.414|
|[[:human genes:s:slc6a17|SLC6A17]]|0.414|
|[[:human genes:t:ticrr|TICRR]]|0.413|
|[[:human genes:u:utp3|UTP3]]|0.413|
|[[:human genes:r:rpl30|RPL30]]|0.412|
|[[:human genes:c:ckap5|CKAP5]]|0.41|
|[[:human genes:l:lrr1|LRR1]]|0.41|
|[[:human genes:d:dhx38|DHX38]]|0.409|
|[[:human genes:r:rrp15|RRP15]]|0.408|
|[[:human genes:n:nol10|NOL10]]|0.408|
|[[:human genes:t:trappc11|TRAPPC11]]|0.408|
|[[:human genes:c:chmp4b|CHMP4B]]|0.408|
|[[:human genes:h:hnrnpc|HNRNPC]]|0.408|
|[[:human genes:n:npipb5|NPIPB5]]|0.406|
|[[:human genes:a:aqr|AQR]]|0.405|
|[[:human genes:c:c1qtnf9b|C1QTNF9B]]|0.405|
|[[:human genes:d:ddx23|DDX23]]|0.405|
|[[:human genes:z:znf830|ZNF830]]|0.404|
|[[:human genes:t:terf2|TERF2]]|0.402|
|[[:human genes:p:psmc6|PSMC6]]|0.401|
|[[:human genes:c:ccna2|CCNA2]]|0.401|
|[[:human genes:c:chaf1a|CHAF1A]]|0.401|
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 211/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|1/1|
|bile duct|7/28|
|blood|9/28|
|bone|8/26|
|breast|6/33|
|central nervous system|11/56|
|cervix|1/4|
|colorectal|8/17|
|esophagus|5/13|
|fibroblast|0/1|
|gastric|6/16|
|kidney|6/21|
|liver|6/20|
|lung|23/75|
|lymphocyte|4/16|
|ovary|5/26|
|pancreas|6/24|
|peripheral nervous system|2/16|
|plasma cell|5/15|
|prostate|0/1|
|skin|7/24|
|soft tissue|3/9|
|thyroid|1/2|
|upper aerodigestive|6/22|
|urinary tract|6/29|
|uterus|1/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 1639
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 5.48 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='EXOSC3 Expression in NALM6 Cells: 5.48'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>